Category: Parkinson's Disease: Non-Motor Symptoms
Objective: The aim of the present study was to identify predictors of clinically significant quality of life (QoL) impairment in Parkinson´s disease (PD) patients from a Spanish cohort.
Background: It is important in clinical practice to know what factors contribute to a worsening of the QoL of PD patients with the intention of being able to carry out interventions.
Method: PD patients recruited from 35 centers of Spain from the COPPADIS cohort from January 2016, to November 2017, were followed-up during 2 years [1]. Health-related QoL (HRQoL) and global QoL (GQoL) were assessed with the 39-item Parkinson’s disease Questionnaire (PDQ-39) and the EUROHIS-QOL 8-item index (EUROHIS-QOL8), respectively, at baseline (V0) and at 24 months ± 1 month (V2). Clinically significant HRQoL and GQoL impairment were defined as presenting an increase and decrement in PDQ-39SI and EUROHIS-QOL8 score at V2 ≥ 10% of the score at baseline (V0), respectively [2]. A comparison with a control group was conducted for GQoL.
Results: GQoL didn´t change significantly neither in PD patients (N=507; p=0.686) nor in the control group (N=119; p=0.192). The mean PDQ-39SI was significantly increased in PD patients (62.7 ± 8.5 years old; 58.8% males; N=500) by 21.6% (from 16.7 ± 13 to 20.3 ± 16.4; p<0.0001) at V2. Ninety-tree patients (18.6%) presented a clinically significant HRQoL impairment at V2. To be younger (OR=0.896; 95%CI, 0.829-0.968; p=0.006) and a woman (OR=4.181; 95%CI, 1.422-12.290; p=0.009), and a greater increase in BDI-II (Beck Depression Inventory – II) (OR=1.139; 95%CI, 1.053-1.231; p=0.001) and NMSS (Non-Motor Symptoms Scale) (OR=1.052; 95%CI, 1.028-1.076; p<0.0001) total scores from V0 to V2 were associated with clinically significant HRQoL impairment at 2 years follow-up, after adjustment to many covariates (Hosmer-Lemeshow test, p=0.665; R2=0.655). Specifically, an increase in ≥ 5 and ≥ 10 points of BDI-II and NMSS total score at V2 multiplied the probability of presenting a clinically significant QoL impairment by 5 (OR=5.453; 95%CI, 1.663-17.876; p=0.005) and 8 (OR=8.217; 95%CI, 2.975-22.696; p=0.002), respectively.
Conclusion: Age, gender, and mood and non-motor symptoms burden impairment were associated with clinically significant HRQoL impairment after 2 years follow-up in PD patients.
References: 1. Santos-García et al.; COPPADIS Study Group. BMC Neurol 2016;16:26. 2. Ringash J et al. Cancer 2007;110:196-202.
To cite this abstract in AMA style:
D. Santos García, C. Cores, T. de Deus, J. Paz González, C. Martínez, E. Suárez, S. Jesús, M. Aguilar, P. Pastor, LL. Planellas, M. Cosgaya, J. García Caldentey, N. Caballol, I. Legarda, J. Hernández Vara, I. Cabo, L. López Manzanares, I. González Aramburu, M. Avila, M. Catalán, V. Nogueira, V. Puente, M. de Arcos, C. Borrué, B. Solano, M. álvarez Sauco, L. Vela, S. Escalante, E. Cubo, F. Carrillo, J. Martínez Castrillo, P. Sánchez Alonso, M. Alonso Losada, N. López Ariztegui, E. Erro, J. Kulisevsky, M. Blázquez, M. Seijo, J. Ruíz Martínez, C. Valero, M. Kurtis, O. de Fábregues, J. González, C. Ordás, L. López Díaz, P. Mir, P. Martínez Martín. Predictors of Clinically Significant Quality of Life Impairment in Parkinson´s Disease. Results from the COPPADIS Cohort at 2 Years Follow-up. [abstract]. Mov Disord. 2021; 36 (suppl 1). https://www.mdsabstracts.org/abstract/predictors-of-clinically-significant-quality-of-life-impairment-in-parkinsons-disease-results-from-the-coppadis-cohort-at-2-years-follow-up/. Accessed June 15, 2025.« Back to MDS Virtual Congress 2021
MDS Abstracts - https://www.mdsabstracts.org/abstract/predictors-of-clinically-significant-quality-of-life-impairment-in-parkinsons-disease-results-from-the-coppadis-cohort-at-2-years-follow-up/